DTS-108, a novel peptidic prodrug of SN38: in vivo efficacy and toxicokinetic studies
- PMID: 18381956
- DOI: 10.1158/1078-0432.CCR-07-4580
DTS-108, a novel peptidic prodrug of SN38: in vivo efficacy and toxicokinetic studies
Abstract
Purpose: Irinotecan is a prodrug converted to the active cytotoxic molecule SN38 predominantly by the action of liver carboxylesterases. The efficacy of irinotecan is limited by this hepatic activation that results in a low conversion rate, high interpatient variability, and dose-limiting gastrointestinal toxicity. The purpose of this study was to evaluate a novel peptidic prodrug of SN38 (DTS-108) developed to bypass this hepatic activation and thus reduce the gastrointestinal toxicity and interpatient variability compared with irinotecan.
Experimental design: SN38 was conjugated to a cationic peptide (Vectocell) via an esterase cleavable linker. The preclinical development plan consisted of toxicity and efficacy evaluation in a number of different models and species.
Results: The conjugate (DTS-108) is highly soluble, with a human plasma half-life of 400 minutes in vitro. Studies in the dog showed that DTS-108 liberates significantly higher levels of free SN38 than irinotecan without causing gastrointestinal toxicity. In addition, the ratio of the inactive SN38-glucuronide metabolite compared with the active SN38 metabolite is significantly lower following DTS-108 administration, compared with irinotecan, which is consistent with reduced hepatic metabolism. In vivo efficacy studies showed that DTS-108 has improved activity compared with irinotecan. A significant dose-dependent antitumoral efficacy was observed in all models tested and DTS-108 showed synergistic effects in combination with other clinically relevant therapeutic agents.
Conclusions: DTS-108 is able to deliver significantly higher levels of SN38 than irinotecan, without the associated toxicity of irinotecan, resulting in an increased therapeutic window for DTS-108 in preclinical models. These encouraging data merit further preclinical and clinical investigation.
Similar articles
-
Comparison of two self-assembled macromolecular prodrug micelles with different conjugate positions of SN38 for enhancing antitumor activity.Int J Nanomedicine. 2015 Mar 23;10:2295-311. doi: 10.2147/IJN.S77957. eCollection 2015. Int J Nanomedicine. 2015. PMID: 25848251 Free PMC article.
-
[Irinotecan pharmacokinetics].Bull Cancer. 1998 Dec;Spec No:11-20. Bull Cancer. 1998. PMID: 9932079 Review. French.
-
Novel SN38 conjugate-forming nanoparticles as anticancer prodrug: in vitro and in vivo studies.J Control Release. 2013 Mar 10;166(2):147-58. doi: 10.1016/j.jconrel.2012.12.019. Epub 2012 Dec 20. J Control Release. 2013. PMID: 23266448
-
SN38 polymeric nanoparticles: in vitro cytotoxicity and in vivo antitumor efficacy in xenograft balb/c model with breast cancer versus irinotecan.Int J Pharm. 2014 Aug 25;471(1-2):485-97. doi: 10.1016/j.ijpharm.2014.05.046. Epub 2014 May 29. Int J Pharm. 2014. PMID: 24879937
-
Prodrug and nanomedicine approaches for the delivery of the camptothecin analogue SN38.J Control Release. 2013 Nov 28;172(1):48-61. doi: 10.1016/j.jconrel.2013.07.022. Epub 2013 Aug 6. J Control Release. 2013. PMID: 23928356 Review.
Cited by
-
Research Progress of SN38 Drug Delivery System in Cancer Treatment.Int J Nanomedicine. 2024 Jan 26;19:945-964. doi: 10.2147/IJN.S435407. eCollection 2024. Int J Nanomedicine. 2024. PMID: 38293612 Free PMC article. Review.
-
Single protein encapsulated SN38 for tumor-targeting treatment.J Transl Med. 2023 Dec 10;21(1):897. doi: 10.1186/s12967-023-04778-0. J Transl Med. 2023. PMID: 38072965 Free PMC article.
-
Cell-Penetrating Peptides (CPPs) as Therapeutic and Diagnostic Agents for Cancer.Cancers (Basel). 2022 Nov 11;14(22):5546. doi: 10.3390/cancers14225546. Cancers (Basel). 2022. PMID: 36428639 Free PMC article. Review.
-
Peptide-based delivery of therapeutics in cancer treatment.Mater Today Bio. 2022 Mar 30;14:100248. doi: 10.1016/j.mtbio.2022.100248. eCollection 2022 Mar. Mater Today Bio. 2022. PMID: 35434595 Free PMC article. Review.
-
Cell-penetrating peptides improve pharmacokinetics and pharmacodynamics of anticancer drugs.Tissue Barriers. 2022 Jan 2;10(1):1965418. doi: 10.1080/21688370.2021.1965418. Epub 2021 Aug 17. Tissue Barriers. 2022. PMID: 34402743 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources